Comparison of Aptamer-Based and Antibody-Based Assays for Protein Quantification in Chronic Kidney Disease

• Published in: Clinical journal of the American Society of Nephrology Vol. 17; no. 3; pp. 350 - 360
• Main Authors: Lopez-Silva, Carolina, Surapaneni, Aditya, Coresh, Josef, Reiser, Jochen, Parikh, Chirag R, Obeid, Wassim, Grams, Morgan E, Chen, Teresa K
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.03.2022
• Subjects: Biomarkers; Cystatin C; Female; Glomerular Filtration Rate; Humans; Interleukin-8; Male; Original; Receptors, Tumor Necrosis Factor; Receptors, Urokinase Plasminogen Activator; Renal Insufficiency; Renal Insufficiency, Chronic; chronic kidney disease; AASK (African American Study of Kidney Disease and Hypertension); biological assay; mortality; antibodies; end-stage renal disease; chronic inflammation
• ISSN: 1555-9041; 1555-905X
• DOI: 10.2215/cjn.11700921

Novel aptamer-based technologies can identify >7000 analytes per sample, offering a high-throughput alternative to traditional immunoassays in biomarker discovery. However, the specificity for distinct proteins has not been thoroughly studied in the context of CKD. We assessed the use of SOMAscan, an aptamer-based technology, for the quantification of eight immune activation biomarkers and cystatin C among 498 African American Study of Kidney Disease and Hypertension (AASK) participants using immunoassays as the gold standard. We evaluated correlations of serum proteins as measured by SOMAscan versus immunoassays with each other and with iothalamate-measured GFR. We then compared associations between proteins measurement with risks of incident kidney failure and all-cause mortality. Six biomarkers (IL-8, soluble TNF receptor superfamily member 1B [TNFRSF1B], cystatin C, soluble TNF receptor superfamily member 1A [TNFRSF1A], IL-6, and soluble urokinase-type plasminogen activator receptor [suPAR]) had non-negligible correlations ( =0.94, 0.93, 0.89, 0.85, 0.46, and 0.23, respectively) between SOMAscan and immunoassay measurements, and three (IL-10, IFN- , and TNF- ) were uncorrelated ( =0.08, 0.07, and 0.02, respectively). Of the six biomarkers with non-negligible correlations, TNFRSF1B, cystatin C, TNFRSF1A, and suPAR were negatively correlated with measured GFR and associated with higher risk of kidney failure. IL-8, TNFRSF1B, cystatin C, TNFRSF1A, and suPAR were associated with a higher risk of mortality both methods. On average, immunoassay measurements were more strongly associated with adverse outcomes than their SOMAscan counterparts. SOMAscan is an efficient and relatively reliable technique for quantifying IL-8, TNFRSF1B, cystatin C, and TNFRSF1A in CKD and detecting their potential associations with clinical outcomes. This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_02_23_CJN11700921.mp3.